MỘT SỐ YẾU TỐ LIÊN QUAN ĐÁP ỨNG CỦA HÓA TRỊ PHÁC ĐỒ PACLITAXEL-CARBOPLATIN TRÊN UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN IIIC, IV

Abstract

Objectives: To evaluate the response and factors related to the response of Paclitaxel - Carboplatin regimen in patients with stage IIIC, IV ovarian carcinoma. Subjects and methods: Retrospective and prospective description of 52 patients with stage IIIC, IV ovarian carcinoma treated with Paclitaxel- Carboplatin from 4/2016 to 4/2022 at Hanoi Oncology Hospital . Results: The response rate of the regimen after 3 cycles was 92.3%, after 6 cycles was 79.3%. The response rate of stage IIIC and IV patients was 91.9% and 66.7%, respectively, this difference was statistically significant with p = 0.036. Response rates with therapeutic doses > 90% and 85 - 90% of standard doses are 90.9% and 50%, respectively, this difference is statistically significant with p = 0.014. The response rate of patients without pleural effusion and with effusion was 91.1% and 42.9%, respectively, this difference was statistically significant with p = 0.007. Response rates in age groups, PS index, are different but not statistically significant. Conclusion: The response rate in the group of patients with earlier stage, full dose treatment, no response pleural effusion is higher. The factors of PS index, age group, and peritoneal effusion gave different response rates but were not statistically significant.